1088 related articles for article (PubMed ID: 26031544)
41. The interaction between BRAF mutation and microsatellite instability (MSI) status in determining survival outcomes after adjuvant 5FU based chemotherapy in stage III colon cancer.
Chouhan H; Sammour T; Thomas ML; Moore JW
J Surg Oncol; 2018 Dec; 118(8):1311-1317. PubMed ID: 30399198
[TBL] [Abstract][Full Text] [Related]
42. Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer.
Kim JE; Hong YS; Ryu MH; Lee JL; Chang HM; Lim SB; Kim JH; Jang SJ; Kim MJ; Yu CS; Kang YK; Kim JC; Kim TW
Cancer Sci; 2011 Sep; 102(9):1706-11. PubMed ID: 21679278
[TBL] [Abstract][Full Text] [Related]
43. Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment.
Taieb J; Svrcek M; Cohen R; Basile D; Tougeron D; Phelip JM
Eur J Cancer; 2022 Nov; 175():136-157. PubMed ID: 36115290
[TBL] [Abstract][Full Text] [Related]
44. Clinical relevance of microsatellite instability in colorectal cancer.
de la Chapelle A; Hampel H
J Clin Oncol; 2010 Jul; 28(20):3380-7. PubMed ID: 20516444
[TBL] [Abstract][Full Text] [Related]
45. [Microsatellite instability. A new predictive marker (?)].
Dietmaier W
Pathologe; 2010 Oct; 31 Suppl 2():268-73. PubMed ID: 20824433
[TBL] [Abstract][Full Text] [Related]
46. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma.
Elsaleh H; Iacopetta B
Clin Colorectal Cancer; 2001 Aug; 1(2):104-9. PubMed ID: 12445368
[TBL] [Abstract][Full Text] [Related]
47. An Insight into Deficient Mismatch Repair Colorectal Cancer Screening in a Romanian Population-A Bi-Institutional Pilot Study.
Lungulescu C; Croitoru VM; Volovat SR; Cazacu IM; Turcu-Stiolica A; Gheonea DI; Sur D; Lungulescu CV
Medicina (Kaunas); 2021 Aug; 57(8):. PubMed ID: 34441055
[No Abstract] [Full Text] [Related]
48. Molecular genetics of microsatellite-unstable colorectal cancer for pathologists.
Chen W; Swanson BJ; Frankel WL
Diagn Pathol; 2017 Mar; 12(1):24. PubMed ID: 28259170
[TBL] [Abstract][Full Text] [Related]
49. Microsatellite instability, prognosis and drug sensitivity of stage II and III colorectal cancer: more complexity to the puzzle.
Tejpar S; Saridaki Z; Delorenzi M; Bosman F; Roth AD
J Natl Cancer Inst; 2011 Jun; 103(11):841-4. PubMed ID: 21597023
[No Abstract] [Full Text] [Related]
50. Pathological complete response with anti-PD-1 therapy in a patient with microsatellite instable high, BRAF mutant metastatic colon cancer: a case report and review of literature.
Sehdev A; Cramer HM; Ibrahim AA; Younger AE; O'Neil BH
Discov Med; 2016 May; 21(117):341-7. PubMed ID: 27355330
[TBL] [Abstract][Full Text] [Related]
51. Prognostic and predictive relevance of microsatellite instability in colorectal cancer.
Storojeva I; Boulay JL; Heinimann K; Ballabeni P; Terracciano L; Laffer U; Mild G; Herrmann R; Rochlitz C
Oncol Rep; 2005 Jul; 14(1):241-9. PubMed ID: 15944796
[TBL] [Abstract][Full Text] [Related]
52. Colorectal cancer due to deficiency in DNA mismatch repair function: a review.
Bellizzi AM; Frankel WL
Adv Anat Pathol; 2009 Nov; 16(6):405-17. PubMed ID: 19851131
[TBL] [Abstract][Full Text] [Related]
53. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status.
Cohen R; Hain E; Buhard O; Guilloux A; Bardier A; Kaci R; Bertheau P; Renaud F; Bibeau F; Fléjou JF; André T; Svrcek M; Duval A
JAMA Oncol; 2019 Apr; 5(4):551-555. PubMed ID: 30452494
[TBL] [Abstract][Full Text] [Related]
54. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.
Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640
[TBL] [Abstract][Full Text] [Related]
55. Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis.
Tomasello G; Ghidini M; Galassi B; Grossi F; Luciani A; Petrelli F
Sci Rep; 2022 Jan; 12(1):1055. PubMed ID: 35058539
[TBL] [Abstract][Full Text] [Related]
56. Mismatch Repair Deficient (dMMR) Colorectal Carcinoma in a Pakistani Cohort: Association With Clinical and Pathological Parameters.
Hashmi AA; Bukhari U; Rizwan R; Faisal F; Kumar R; Malik UA; Zia S; Khan AR; Sham S; Irfan M
Cureus; 2023 Aug; 15(8):e42781. PubMed ID: 37664303
[TBL] [Abstract][Full Text] [Related]
57. Prognostic and predictive impact of DNA mismatch repair in the management of colorectal cancer.
Sinicrope FA; Yang ZJ
Future Oncol; 2011 Mar; 7(3):467-74. PubMed ID: 21417908
[TBL] [Abstract][Full Text] [Related]
58. Microsatellite Stable Colorectal Cancer With an Immunogenic Phenotype: Challenges in Diagnosis and Treatment.
Saller J; Qin D; Felder S; Coppola D
Clin Colorectal Cancer; 2020 Jun; 19(2):123-131. PubMed ID: 32171644
[TBL] [Abstract][Full Text] [Related]
59. Next-generation sequencing reveals heterogeneous genetic alterations in key signaling pathways of mismatch repair deficient colorectal carcinomas.
Wang J; Li R; He Y; Yi Y; Wu H; Liang Z
Mod Pathol; 2020 Dec; 33(12):2591-2601. PubMed ID: 32620917
[TBL] [Abstract][Full Text] [Related]
60. MSI/MMR-deficient tumor diagnosis: Which standard for screening and for diagnosis? Diagnostic modalities for the colon and other sites: Differences between tumors.
Svrcek M; Lascols O; Cohen R; Collura A; Jonchère V; Fléjou JF; Buhard O; Duval A
Bull Cancer; 2019 Feb; 106(2):119-128. PubMed ID: 30713006
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
